iBio Statistics
Share Statistics
iBio has 9.15M shares outstanding. The number of shares has increased by 330.1% in one year.
| Shares Outstanding | 9.15M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.14M |
| Failed to Deliver (FTD) Shares | 2.69K |
| FTD / Avg. Volume | 1.92% |
Short Selling Information
The latest short interest is 260.10K, so 2.84% of the outstanding shares have been sold short.
| Short Interest | 260.10K |
| Short % of Shares Out | 2.84% |
| Short % of Float | 2.85% |
| Short Ratio (days to cover) | 1.14 |
Valuation Ratios
The PE ratio is -0.31 and the forward PE ratio is -1.55.
| PE Ratio | -0.31 |
| Forward PE | -1.55 |
| PS Ratio | 34.22 |
| Forward PS | 10.6 |
| PB Ratio | 0.36 |
| P/FCF Ratio | -0.41 |
| PEG Ratio | n/a |
Enterprise Valuation
iBio Inc. has an Enterprise Value (EV) of 20.24M.
| EV / Earnings | -0.81 |
| EV / Sales | 89.97 |
| EV / EBITDA | -1.44 |
| EV / EBIT | -1.22 |
| EV / FCF | -1.08 |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.05.
| Current Ratio | 4.08 |
| Quick Ratio | 4.08 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.41 |
| Cash Flow / Debt | -18.86 |
| Interest Coverage | -96.71 |
Financial Efficiency
Return on equity (ROE) is -1.17% and return on capital (ROIC) is -64.51%.
| Return on Equity (ROE) | -1.17% |
| Return on Assets (ROA) | -0.87% |
| Return on Capital (ROIC) | -64.51% |
| Revenue Per Employee | 14.06K |
| Profits Per Employee | -1.56M |
| Employee Count | 16 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 79.07% in the last 52 weeks. The beta is -3.37, so iBio 's price volatility has been lower than the market average.
| Beta | -3.37 |
| 52-Week Price Change | 79.07% |
| 50-Day Moving Average | 2.62 |
| 200-Day Moving Average | 2.14 |
| Relative Strength Index (RSI) | 40.89 |
| Average Volume (20 Days) | 140.36K |
Income Statement
In the last 12 months, iBio had revenue of $225.00K and earned -$24.91M in profits. Earnings per share was $-6.5.
| Revenue | 225.00K |
| Gross Profit | 225.00K |
| Operating Income | -16.63M |
| Net Income | -24.91M |
| EBITDA | -14.02M |
| EBIT | -16.63M |
| Earnings Per Share (EPS) | -6.5 |
Balance Sheet
The company has $14.21M in cash and $4.46M in debt, giving a net cash position of $9.75M.
| Cash & Cash Equivalents | 14.21M |
| Total Debt | 4.46M |
| Net Cash | 9.75M |
| Retained Earnings | -313.85M |
| Total Assets | 24.52M |
| Working Capital | 8.24M |
Cash Flow
In the last 12 months, operating cash flow was -$18.55M and capital expenditures -$210.00K, giving a free cash flow of -$18.76M.
| Operating Cash Flow | -18.55M |
| Capital Expenditures | -210.00K |
| Free Cash Flow | -18.76M |
| FCF Per Share | -4.9 |
Margins
Gross margin is 100%, with operating and profit margins of -7.39K% and -11.07K%.
| Gross Margin | 100% |
| Operating Margin | -7.39K% |
| Pretax Margin | -6.86K% |
| Profit Margin | -11.07K% |
| EBITDA Margin | -6.23K% |
| EBIT Margin | -7.39K% |
| FCF Margin | -8.34K% |
Dividends & Yields
IBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -281.39% |
| FCF Yield | -88.78% |
Analyst Forecast
The average price target for IBIO is $4.3, which is 86.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.3 |
| Price Target Difference | 86.1% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Nov 29, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Nov 29, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -17.53 |
| Piotroski F-Score | 4 |